



Advanced Research in Age-Related Macular Degeneration (AMD)

Guest Editor:

Dr. Oyuna Kozhevnikova

Institute of Cytology and
Genetics, Siberian Branch of
Russian Academy of Sciences,
630090 Novosibirsk, Russia

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

Age-related macular degeneration (AMD) is an eye disease that is the main cause of irreversible vision loss in people over 60 years of age. AMD is a disease of a complex nature, the development of which is controlled by many interacting genetic and environmental factors that determine the form, rate of disease progression, and response to therapy.

The pathogenesis of AMD is based on a decrease in metabolic and regenerative processes characteristic of aging, a violation of the microcirculation and structural organization of the retina, the prerequisites and mechanisms for the transition of which into the pathological process remain unclear. Therefore, studies of the molecular mechanisms of AMD pathogenesis and new approaches to its early diagnostics, treatments, and prevention are urgently needed. In this Special Issue of the journal *Biomedicines*, we would like to invite you to provide original clinical and experimental studies and reviews on all aspects related to the theme of “Advanced Research in AMD”. Submissions dealing with the topics mentioned in the keywords listed below are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)